RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Announces Additional Synthesized Compounds in its AI-Driven Cancer Drug Discovery Program
February 06, 2025 08:30 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on DNA-damage response...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Announces Listing on Frankfurt Stock Exchange
January 30, 2025 12:16 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics to Participate in BioInnovate UBC Annual Conference
January 29, 2025 08:30 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company advancing innovative cancer therapies through artificial...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Announces Key Milestone in Cancer Drug Innovation in Collaboration with Variational AI
January 13, 2025 08:30 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Presents AI-Driven Drug Discovery Research at Society for Neuro-Oncology Annual Meeting
November 25, 2024 07:30 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer...